Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | IL6 | P05231 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.32 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631218 | 0.88 | LGALS3 (0.35) | LGALS3TNFIL6LMNATSHR | |
| SCHEMBL16631241 | 0.87 | SYNJ2 (0.38) | LMNATSHRSLC5A2B4GALT1P2RY14 | |
| SCHEMBL16631846 | 0.86 | TSHR (0.32) | LMNATSHR | |
| SCHEMBL16631821 | 0.85 | TNF (0.37) | LGALS3TNFIL6LMNATSHR | |
| SCHEMBL16631175 | 0.84 | CDA (0.35) | TNFIL6LMNATSHRSLC5A2 | |
| SCHEMBL16631817 | 0.84 | TNF (0.36) | LGALS3TNFIL6LMNATSHR | |
| SCHEMBL18080009 | 0.82 | P2RY2 (0.48) | B4GALT1P2RY14 | |
| SCHEMBL16631508 | 0.81 | TNF (0.32) | TNFIL6LMNATSHRLGALS8 | |
| SCHEMBL16631572 | 0.79 | SLC5A2 (0.37) | LGALS3SLC5A2LGALS8LGALS1 | |
| SCHEMBL16631596 | 0.77 | PYGL (0.33) | LGALS3TNFIL6SLC5A2LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | LGALS3 2438/4885TNF 4770/4885IL6 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.